Evidence map›Paper›PMID 42534246›Full record

ReviewCureus2026

Targeting Neurovascular Inflammation in Rosacea: A Systematic Review of Botulinum Toxin Therapy.

Foteini Moniati, Chistos Costa, Constantina Chatzimatthaiou, Michaela Pishia, Maria Vassiliou, Marios Chatzimatthaiou

Abstract readReview
In one paragraph

Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Foteini MoniatiDepartment of Inflammation and Aging, University of Birmingham, Birmingham, GBR.
Chistos CostaDepartment of Medicine, Oxford University Hospitals NHS Trust, Oxford, GBR.
Constantina ChatzimatthaiouDepartment of Medicine, Medway NHS Foundation Trust, Gillingham, GBR.
Michaela PishiaDepartment of Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, GBR.
Maria VassiliouDepartment of Medicine, Barts and the London School of Medicine and Dentistry, London, GBR.
Marios ChatzimatthaiouDepartment of Medicine, Barts and the London School of Medicine and Dentistry, London, GBR.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rosacea is a chronic inflammatory dermatosis characterized by persistent erythema and episodic flushing, often associated with suboptimal treatment outcomes and frequent recurrence. Botulinum toxin has recently been proposed as a novel therapeutic modality in its management. This systematic review evaluates the current evidence regarding the efficacy and safety of botulinum toxin in patients with rosacea. A comprehensive search of major electronic databases was conducted to identify relevant studies assessing its clinical application. Overall, the available literature suggests that botulinum toxin is associated with improvements in clinical signs and symptoms, particularly erythema, with effects sustained for a variable duration. Reported adverse events were predominantly mild and self-limiting. However, interpretation of these findings is limited by small sample sizes, heterogeneity in study design, and relatively short follow-up periods. Further high-quality, standardized studies are required to better define its role in routine clinical practice.

Indexed as

botoxbotulinum toxinmedical dermatologyrosaceasystematic review

Identifiers

PMID42534246
PMCPMC13419864

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.